Clinical trials: SCC - Squamous Cell Carcinoma
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Solid Tumors
A Study of E7130 in Participants With Solid Tumors
The primary objective of this study is to evaluate the tolerability and safety profile of E7130 in participants with solid tumors.
- Trial name
- NCT03444701
- Testing
- E7130
- Where
- 9 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Eisai Co., Ltd.
Non-melanoma Skin Cancer, Basal Cell Carcinoma
EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds
The purpose of study is to assess the safety and performance of EktoTherix™ Tissue Repair Scaffold in the treatment of full-thickness, dermatologic wounds created by the surgical removal of non-melanoma skin cancers.
- Conditions
- Non-melanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- NCT02409628
- Testing
- EktoTherix
- Where
- 3 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Neotherix Limited
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR kinase inhibitors) in patients with advanced tumors unresponsive to standard…
- Conditions
- Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma
- Trial name
- NCT01353625
- Testing
- CC-115
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 118 people
- Sponsor
- Celgene
Carcinoma, Non-Small-Cell Lung
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
The main objective is to assess the efficacy of afatinib in combination with pembrolizumab, as measured by objective response (OR) in patients with locally advanced or metastatic squamous NSCLC who progressed during or after…
- Trial name
- LUX-Lung-IO (NCT03157089)
- Testing
- Afatinib, pembrolizumab
- Where
- 13 sites in United States, France and 3 more
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Nonsmall Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy
A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy
- Trial name
- NCT02972216
- Testing
- Nolbaxol, Taxotere, cisplatin
- Volunteers
- 40 people
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Head and Neck Squamous Cell Carcinoma
A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with an annual incidence of approximately 700,000 cases.
- Trial name
- NCT07744126
- Testing
- Telisotuzumab Adizutecan, Pembrolizumab, Carboplatin
- Where
- 5 sites in United States, Japan and 1 more
- Volunteers
- 150 people
- Sponsor
- AbbVie
Solid Tumor, Colorectal Cancer (CRC)
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
- Conditions
- Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- ODIN (NCT07151040)
- Testing
- TH9619
- Where
- 4 sites in France, Spain and 1 more
- Volunteers
- 43 people
- Sponsor
- One-carbon Therapeutics AB
Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative
Intratumoral N17350 in Advanced Solid Tumors
The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies.
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma
- Trial name
- OP-NEU-101 (NCT07339176)
- Testing
- N17350
- Where
- 9 sites in United States, Australia
- Volunteers
- 275 people
- Sponsor
- Onchilles Pharma Inc
Advanced Solid Tumors
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
To better understand the safety and tolerability of ALKS 4230 in humans
- Trial name
- NCT02799095
- Testing
- ALKS 4230, ALKS 4230 + pembrolizumab
- Where
- 31 sites in United States, Australia and 5 more
- Volunteers
- 243 people
- Sponsor
- Mural Oncology, Inc
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Head and Neck Squamous Cell Carcinoma
Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC
A phase II study to evaluate the efficacy and safety of Docetaxel-PM in recurrent or metastatic head and neck squamous cell carcinoma
- Trial name
- NCT02639858
- Testing
- Docetaxel-PM
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced non-melanoma skin cancers will receive a fixed dose of 0.1 mg of…
- Conditions
- Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers
- Trial name
- NCT04160065
- Testing
- IFx-Hu2.0
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- TuHURA Biosciences, Inc.
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
Head and Neck Squamous Cell Carcinoma
TRACE: Tirapazamine-Radiation And Cisplatin Evaluation
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
- Trial name
- TRACE (NCT00174837)
- Testing
- Tirapazamine, Cisplatin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Head and Neck Squamous Cell Carcinoma
Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors
Part1: A mutilpe-center, open-label, Phase II clinical trial to evaluate the efficacy and the safety of HLX10 in combination with HLX07 in patients with advanced advanced head and neck tumors.
- Trial name
- NCT04297995
- Testing
- HLX10, HLX07, Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Shanghai Henlius Biotech
Esophageal Squamous Cell Carcinoma
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
This trial is a registrational Phase II/III, randomized, controlled, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with tislelizumab ± 5-FU in patients with unresectable, locally…
- Trial name
- NCT07554456
- Testing
- BL-B01D1, Tislelizumab, 5-Fluorouracil
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer, Colorectal Cancer
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04045496
- Testing
- JAB-3312
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Carcinoma, Squamous Cell
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
The aim of this prospective, observational, multicenter, post-marketing study is to evaluate the safety and efficacy of Cetuximab (Erbitux) in combination with platinum based chemotherapy, in the first line therapy of recurrent/…
- Trial name
- NCT01142869
- Testing
- Cetuximab
- Where
- 28 sites in India
- Volunteers
- 133 people
- Sponsor
- Merck KGaA, Darmstadt, Germany